Primecap Management
FOLD

Primecap Management’s Amicus Therapeutics FOLD Stock Holding History

Primecap Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.46M Sell
585,400
-4,000
-0.7% -$57.3K 0.01% 267
2025
Q4 		$8.39M Sell
589,400
-78,500
-12% -$771K 0.01% 262
2025
Q3 		$5.26M Sell
667,900
-128,200
-16% -$912K ﹤0.01% 282
2025
Q2 		$4.56M Sell
796,100
-123,400
-13% -$796K ﹤0.01% 287
2025
Q1 		$7.5M Sell
919,500
-15,300
-2% -$142K 0.01% 266
2024
Q4 		$8.81M Sell
934,800
-94,000
-9% -$977K 0.01% 258
2024
Q3 		$11M Sell
1,028,800
-23,700
-2% -$258K 0.01% 258
2024
Q2 		$10.4M Sell
1,052,500
-41,700
-4% -$428K 0.01% 256
2024
Q1 		$12.9M Hold
1,094,200
– – 0.01% 251
2023
Q4 		$15.5M Hold
1,094,200
– – 0.01% 240
2023
Q3 		$13.3M Hold
1,094,200
– – 0.01% 246
2023
Q2 		$13.7M Sell
1,094,200
-59,200
-5% -$702K 0.01% 246
2023
Q1 		$12.8M Hold
1,153,400
– – 0.01% 244
2022
Q4 		$14.1M Sell
1,153,400
-174,800
-13% -$1.97M 0.01% 235
2022
Q3 		$13.9M Hold
1,328,200
– – 0.01% 229
2022
Q2 		$14.3M Sell
1,328,200
-100,400
-7% -$827K 0.01% 234
2022
Q1 		$13.5M Sell
1,428,600
-99,400
-7% -$932K 0.01% 250
2021
Q4 		$17.6M Sell
1,528,000
-98,100
-6% -$1.09M 0.01% 247
2021
Q3 		$15.5M Sell
1,626,100
-218,900
-12% -$2.24M 0.01% 252
2021
Q2 		$17.8M Sell
1,845,000
-285,000
-13% -$2.78M 0.01% 242
2021
Q1 		$21M Hold
2,130,000
– – 0.01% 236
2020
Q4 		$49.2M Hold
2,130,000
– – 0.04% 190
2020
Q3 		$30.1M Hold
2,130,000
– – 0.02% 194
2020
Q2 		$32.1M Sell
2,130,000
-131,000
-6% -$1.6M 0.03% 183
2020
Q1 		$20.9M Sell
2,261,000
-34,000
-1% -$323K 0.02% 189
2019
Q4 		$22.4M Buy
2,295,000
+97,500
+4% +$893K 0.02% 208
2019
Q3 		$17.6M Buy
+2,197,500
New +$23.9M 0.01% 208

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Primecap Management's FOLD Position: Q1 2026 in Review

Primecap Management reduced its Amicus Therapeutics (FOLD) stake by 0.68% in Q1 2026, selling an estimated $57.3K and leaving 585,400 shares worth $8.46M. The position accounts for 0.01% of the portfolio, ranked #267.

Primecap Management first reported a position in FOLD in Q3 2019 and has held it in 27 quarters since. The position peaked at $49.2M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Primecap Management held 585,400 shares of Amicus Therapeutics worth $8.46M as of Q1 2026.
  • Primecap Management sold 4,000 Amicus Therapeutics shares in Q1 2026, an estimated $57.3K.
  • Amicus Therapeutics made up 0.01% of Primecap Management's portfolio in Q1 2026, its #267 holding.
  • Primecap Management first reported a position in Amicus Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Primecap Management's Amicus Therapeutics position peaked at $49.2M in Q4 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Primecap Management's 13F filing for Q1 2026, filed 11 May 2026.